JP2008535785A - Ｓｔａｔ３の小分子阻害剤およびその使用 - Google Patents

Ｓｔａｔ３の小分子阻害剤およびその使用 Download PDF

Info

Publication number
JP2008535785A
JP2008535785A JP2007557196A JP2007557196A JP2008535785A JP 2008535785 A JP2008535785 A JP 2008535785A JP 2007557196 A JP2007557196 A JP 2007557196A JP 2007557196 A JP2007557196 A JP 2007557196A JP 2008535785 A JP2008535785 A JP 2008535785A
Authority
JP
Japan
Prior art keywords
apoptosis
sta
stat3
cancer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007557196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535785A5 (enExample
Inventor
フイ ソン
レンツァオ ワン
シャオメン ワン
ジアーユ リン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of JP2008535785A publication Critical patent/JP2008535785A/ja
Publication of JP2008535785A5 publication Critical patent/JP2008535785A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007557196A 2005-02-25 2006-02-24 Ｓｔａｔ３の小分子阻害剤およびその使用 Withdrawn JP2008535785A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65659705P 2005-02-25 2005-02-25
PCT/US2006/006637 WO2006091837A2 (en) 2005-02-25 2006-02-24 Small molecule inhibitors of stat3 and the uses thereof

Publications (2)

Publication Number Publication Date
JP2008535785A true JP2008535785A (ja) 2008-09-04
JP2008535785A5 JP2008535785A5 (enExample) 2009-04-09

Family

ID=36928057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007557196A Withdrawn JP2008535785A (ja) 2005-02-25 2006-02-24 Ｓｔａｔ３の小分子阻害剤およびその使用

Country Status (7)

Country Link
US (1) US20060247318A1 (enExample)
EP (1) EP1853242A4 (enExample)
JP (1) JP2008535785A (enExample)
CN (1) CN101511179A (enExample)
AU (1) AU2006216510A1 (enExample)
CA (1) CA2599393A1 (enExample)
WO (1) WO2006091837A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2625891A1 (en) 2005-10-14 2007-04-26 Carlton D. Donald Inhibition of pax2 by defb1 induction as a therapy for cancer
US7857804B2 (en) * 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
DK2120958T3 (da) 2006-12-06 2013-07-01 Univ Central Florida Res Found Stat3-inhibitor med anticancer-aktivitet og associerede fremgangsmåder
JP5653042B2 (ja) * 2007-01-16 2015-01-14 ムスク ファウンデーション フォー リサーチ デベロップメント 前立腺病変の診断、治療、及び予防用組成物及び方法
WO2009032338A1 (en) * 2007-09-09 2009-03-12 University Of Florida Research Foundation Apratoxin therapeutic agents: mechanism and methods of treatment
WO2009032351A1 (en) * 2007-09-09 2009-03-12 University Of Florida Research Foundation Natural product agents, derivatives, and methods of treatment
CA2736564A1 (en) 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
WO2009042677A2 (en) * 2007-09-24 2009-04-02 Farjo Rafal A Stat3 inhibiting compositions and methods
US8450337B2 (en) 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
JP2013522326A (ja) 2010-03-19 2013-06-13 ボストン バイオメディカル， インコーポレイテッド がん幹細胞を標的とするための新規の方法
KR101273747B1 (ko) * 2010-09-09 2013-06-12 가톨릭대학교 산학협력단 Ｓｔａ-21을 유효성분으로 함유하는 관절염의 예방 및 치료용 조성물
CN102961374B (zh) * 2012-12-12 2015-01-14 苏州大学 一种化合物的应用以及stat3抑制剂
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
WO2015120436A2 (en) 2014-02-10 2015-08-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 phosphorylation during graft-versus-host disease
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CN106822898B (zh) * 2017-02-17 2018-09-25 王晓华 靶向下调stat3基因表达在提高肺腺癌化疗敏感性方面的应用
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
CN109988125B (zh) * 2018-10-25 2022-03-18 河南省锐达医药科技有限公司 一类新型苯甲酰苯胺化合物的制备方法和在肿瘤治疗上的应用
MX2021012216A (es) 2019-04-05 2022-01-24 Kymera Therapeutics Inc Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
US20230192786A1 (en) * 2020-05-15 2023-06-22 Glg Pharma, Llc Stat3 inhibition for treatment and prevention of human coronavirus infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491588A (en) * 1982-03-31 1985-01-01 University Of Tennessee Research Corporation Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics
AU2736400A (en) * 1999-01-27 2000-08-18 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy

Also Published As

Publication number Publication date
WO2006091837A2 (en) 2006-08-31
EP1853242A2 (en) 2007-11-14
EP1853242A4 (en) 2009-11-18
AU2006216510A1 (en) 2006-08-31
CN101511179A (zh) 2009-08-19
US20060247318A1 (en) 2006-11-02
CA2599393A1 (en) 2006-08-31
WO2006091837A3 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
JP2008535785A (ja) Ｓｔａｔ３の小分子阻害剤およびその使用
JP7505761B2 (ja) Ｔ細胞疲弊を阻害するための組成物および方法
JP5399904B2 (ja) Ｍｄｍ２の小分子阻害剤およびその使用
Mao et al. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT
KR102389552B1 (ko) Mdm2 저해제 및 이 저해제를 사용하는 치료 방법
ES2624808T3 (es) Antagonistas de MDM2 espirooxindólicos
JP2008511548A (ja) 抗アポトーシスｂｃｌ−２ファミリーメンバーの低分子阻害剤およびその使用法
US20100093645A1 (en) SMAC Peptidomimetics and the Uses Thereof
Tirado et al. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo
JP2010529023A (ja) 疾患の処置のためのゴシポールの律動的投薬法
AU2015362670A1 (en) Small molecule inhibitors of EGFR and PI3K
AU2009200387A1 (en) Gossypol co-crystals and the use thereof
CN101160314A (zh) Mdm2的小分子抑制剂以及其应用
ES2657649T3 (es) Inhibidores de Mcl-1 de molécula pequeña y sus usos
Liu et al. Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor
Ding et al. Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells
JP2008533039A (ja) 抗アポトーシスＢｃｌ−２ファミリーメンバーのクロメン−４−オン阻害剤およびその使用
CN101132783B (zh) 阿朴棉子酚酮及其用途
AU2017354019A1 (en) Small molecule dual inhibitors of EGFR/PI3K and uses thereof
CN103191095B (zh) 一种stat3信号通路小分子抑制剂及其在制备抗肿瘤药物中的应用
WO2017031116A1 (en) Small molecule inhibitors of ku70/80 and uses thereof
JP2019510084A (ja) 小分子型の活性酸素種誘導剤及びミトコンドリア活性阻害剤
US20240124419A1 (en) Small molecule inhibitors of grp78 and uses thereof
WO2012078982A2 (en) Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
WO2021011778A1 (en) Small molecule inhibitors of ku70/80 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090220

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090826